Literature DB >> 11212358

The pleiotropic functions of aspirin: mechanisms of action.

A R Amin1, M G Attur, M Pillinger, S B Abramson.   

Abstract

Recent studies have suggested that aspirin and aspirin-like compounds have a variety of actions in addition to their well-studied ability to inhibit cyclooxygenases. These actions include inhibition of the uncoupling of oxidative phosphorylation, decreases in adenosine triphosphate stores. increases in extracellular adenosine, downregulation of the expression and activity of inducible nitric oxide synthetase, inhibition and/or stimulation of various mitogen-activated protein kinase activities and inhibition of nuclear factor binding kappaB site (NF-kappaB) activation. Moreover, aspirin-like compounds have recently been shown to have previously unappreciated clinical and biological effects, some apparently independent of cyclooxygenase. In this review we discuss the various mechanisms of action of aspirin-like compounds and their relevance to clinical disease and therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11212358     DOI: 10.1007/s000180050432

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  12 in total

1.  Aspirin use for primary prophylaxis: Adverse outcomes in non-variceal upper gastrointestinal bleeding.

Authors:  Karina M Souk; Hani M Tamim; Hussein A Abu Daya; Don C Rockey; Kassem A Barada
Journal:  World J Gastrointest Surg       Date:  2016-07-27

2.  Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas.

Authors:  Gloria Y F Ho; Xiaonan Xue; Mary Cushman; Gail McKeown-Eyssen; Robert S Sandler; Dennis J Ahnen; Elizabeth L Barry; Fred Saibil; Robert S Bresalier; Thomas E Rohan; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-10-12       Impact factor: 13.506

3.  Positive influence of aspirin on coronary endothelial function: Importance of the dose.

Authors:  Hiroki Teragawa; Naoya Mitsuba; Ken Ishibashi; Satoshi Kurisu; Yasuki Kihara
Journal:  World J Cardiol       Date:  2013-11-26

4.  Adaptive in vivo device for theranostics of inflammation: Real-time monitoring of interferon-γ and aspirin.

Authors:  Chaomin Cao; Ronghua Jin; Hui Wei; Zhongning Liu; Shengnan Ni; Guo-Jun Liu; Howard A Young; Xin Chen; Guozhen Liu
Journal:  Acta Biomater       Date:  2019-10-15       Impact factor: 8.947

Review 5.  Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients?

Authors:  Federico Cacciapuoti; Fulvio Cacciapuoti
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

6.  AA/12-Lipoxygenase Signaling Contributes to Inhibitory Learning in Hermissenda Type B Photoreceptors.

Authors:  Tony L Walker; Joanna J Campodonico; Joel S Cavallo; Joseph Farley
Journal:  Front Behav Neurosci       Date:  2010-08-03       Impact factor: 3.558

7.  Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability.

Authors:  S Ellero-Simatos; J P Lewis; A Georgiades; L M Yerges-Armstrong; A L Beitelshees; R B Horenstein; A Dane; A C Harms; R Ramaker; R J Vreeken; C G Perry; H Zhu; C L Sànchez; C Kuhn; T L Ortel; A R Shuldiner; T Hankemeier; R Kaddurah-Daouk
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-07-16

Review 8.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Authors:  Vanessa Bianconi; Francesco Violi; Francesca Fallarino; Pasquale Pignatelli; Amirhossein Sahebkar; Matteo Pirro
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

9.  Effect of Low-Dose Aspirin on Soluble FMS-Like Tyrosine Kinase 1/Placental Growth Factor (sFlt-1/PlGF Ratio) in Pregnancies at High Risk for the Development of Preeclampsia.

Authors:  Karoline Mayer-Pickel; Vassiliki Kolovetsiou-Kreiner; Christina Stern; Julia Münzker; Katharina Eberhard; Slave Trajanoski; Ioana-Claudia Lakovschek; Daniela Ulrich; Bence Csapo; Uwe Lang; Barbara Obermayer-Pietsch; Mila Cervar-Zivkovic
Journal:  J Clin Med       Date:  2019-09-10       Impact factor: 4.241

10.  FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Ahmed Mostafa; Ahmed Kandeil; Yaseen A M M Elshaier; Omnia Kutkat; Yassmin Moatasim; Adel A Rashad; Mahmoud Shehata; Mokhtar R Gomaa; Noura Mahrous; Sara H Mahmoud; Mohamed GabAllah; Hisham Abbas; Ahmed El Taweel; Ahmed E Kayed; Mina Nabil Kamel; Mohamed El Sayes; Dina B Mahmoud; Rabeh El-Shesheny; Ghazi Kayali; Mohamed A Ali
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.